AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Multiple Myeloma Hub
What are the pros and cons of bispecific antibodies for multiple myeloma?
Jul 25, 2022
Experts Roberto Mina and Andrzej J. Jakubowiak discuss the pros and cons of bispecific antibodies for multiple myeloma, highlighting MajesTEC-1 and MagnetisMM-1 trials, efficacy, response rates, challenges like infection risks, comparison to CAR T-cell therapies, and sequencing of therapies in myeloma treatment.
27:57
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Bi-specific antibodies show promising efficacy comparable to CAR-T therapy in multiple myeloma treatment.
- Careful monitoring is needed to manage infection risks and CRS challenges associated with bi-specific antibodies for multiple myeloma.
Deep dives
Efficacy and Response Rates of Bi-Specific Antibodies
Bi-specific antibodies show high efficacy with around two-thirds of patients responding and one-third achieving complete remission, even in heavily pre-treated populations. Results indicate promising efficacy comparable to CAR-T therapy, especially after previous BCMA targeting therapies. Alternative targeting strategies like GPRC5D also show promising activity, suggesting the potential for sequence or combination treatments.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode